Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04789174 · ClinicalTrials.gov registry record · Phase 4
Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study
A Phase 4 study of Obstructive Sleep Apnea and Excessive Daytime Sleepiness, sponsored by Axsome Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 59
- Enrollment target
- 20
- Study locations
NCT04789174 is a Phase 4 study of Obstructive Sleep Apnea and Excessive Daytime Sleepiness that has completed, run by Axsome Therapeutics. The registered enrollment target is 59 participants, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (73% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT04789174, a Phase 4 study of Obstructive Sleep Apnea and Excessive Daytime Sleepiness, has completed, sponsored by Axsome Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 59 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) plus impaired cognitive function.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Solriamfetol
Study Locations (20)
California
- Southern California Institute for Respiratory Disease - Los Angeles
- SDS Clinical Trials, Inc - Santa Ana
Georgia
- NeuroTrials Research Inc - Atlanta
- The Neurological Center of north Georgia. - Gainesville
Ohio
- CTI-Clinical Research Center - Cincinnati
- Intrepid Research, LLC - Cincinnati
Texas
- FutureSearch Trials of Neuroglogy - Austin
- Sleep Therapy & Research Center - San Antonio
Ontario
- MedSleep Inc. o/a Toronto Sleep Institute - Toronto
- Jodha Tishon Inc - Toronto
Florida
- Clinical Neuroscience Solutions, Inc - Jacksonville
Maryland
- The Center for Sleep & Wake Disorders - Chevy Chase
Michigan
- Henry Ford Health System - Novi
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2021-05-17 |
| Est. Completion | 2022-09-19 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04789174
The ClinicalTrials.gov registry entry for NCT04789174 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 221-participant average among 155 other Obstructive Sleep Apnea trials with a reported enrollment target (73% lower). The listed sponsor is Axsome Therapeutics, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 3 conditions, with Obstructive Sleep Apnea appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04789174 reports 20 study locations spanning 15 distinct geographic areas - top geographies include California, Georgia, Ohio.
Frequently Asked Questions
What is clinical trial NCT04789174 about?
NCT04789174 is a clinical study titled "Solriamfetol's Effect on Cognitive Health in Apnea Participants During a Randomized Placebo-controlled Study". The purpose of study JZP110-405 is to determine whether solriamfetol is effective at improving cognitive function in participants with excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA) plus impaired cognitive function.
What is the current status of trial NCT04789174?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 59 participants. The study started on 2021-05-17. Estimated completion is 2022-09-19.
What conditions does trial NCT04789174 study?
This clinical trial studies the following conditions: Obstructive Sleep Apnea, Excessive Daytime Sleepiness, Impaired Cognitive Function.
What interventions are being tested in trial NCT04789174?
The interventions under investigation include: Placebo (DRUG), Solriamfetol (DRUG).
Who is sponsoring clinical trial NCT04789174?
This trial is sponsored by Axsome Therapeutics, which has 28 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04789174 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Maryland, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obstructive Sleep Apnea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Improving Outcomes in Pediatric Obstructive Sleep Apnea With Computational Fluid Dynamics
RECRUITING · Phase 4
-
Study of Pantoprazole for Sleepiness Associated With Acid Reflux and Sleep Apnea
COMPLETED · Phase 4
-
Impact of Positive Airway Pressure Therapy on Clinical Outcomes in Older Veterans With Chronic Obstructive Pulmonary Disease and Comorbid Obstructive Sleep Apnea (Overlap Syndrome)
RECRUITING · NA
-
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
RECRUITING · Phase 1
-
Effect of CPAP on Blood Pressure in Excessively Sleepy Obstructive Sleep Apnea Subtype
RECRUITING
-
Cognition After OSA Treatment Among Native American People (CATNAP)
RECRUITING · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.